CTOs on the Move

Medizone International

www.medizoneint.com

 
Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets, through its expanding distributor network. The ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.medizoneint.com
  • 350 East Michigan Avenue Suite 500
    Kalamazoo, MI USA 49007
  • Phone: 269.202.5020

Executives

Name Title Contact Details

Similar Companies

Aratana Therapeutics

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for cats and dogs.

CanAm Bioresearch

CanAm Bioresearch is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AandA Phamachem

A&A Phamachem Inc. is a Nepean, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Institute for Therapy through the Arts

The Institute for Therapy through the Arts offers art therapy, music therapy, dance therapy, and drama therapy in Evanston, IL 60201 and Chicagoland.

Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.